TR199902315T2 - Its use as a quinoline-2-carboxylic acid and excitatory amino acid antagonist. - Google Patents

Its use as a quinoline-2-carboxylic acid and excitatory amino acid antagonist.

Info

Publication number
TR199902315T2
TR199902315T2 TR1999/02315T TR9902315T TR199902315T2 TR 199902315 T2 TR199902315 T2 TR 199902315T2 TR 1999/02315 T TR1999/02315 T TR 1999/02315T TR 9902315 T TR9902315 T TR 9902315T TR 199902315 T2 TR199902315 T2 TR 199902315T2
Authority
TR
Turkey
Prior art keywords
quinoline
carboxylic acid
antagonist
excitatory amino
amino acid
Prior art date
Application number
TR1999/02315T
Other languages
Turkish (tr)
Inventor
Di Fabio Romano
Bertani Barbara
Alvaro Giuseppe
Original Assignee
Glaxo Wellcome Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome Spa filed Critical Glaxo Wellcome Spa
Publication of TR199902315T2 publication Critical patent/TR199902315T2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Uyarici amino asitlerin antagonisti olan E 4-(4-asetilamino-fenilkarbamoilmetilen)-5,7- dikloro-1,2,3,4-tetrahidro kuinolin 2-karboksilik asitin (+) enantiomeri ve tuzu, bunlari hazirlamak için islemler, bunlari içeren farmasötik bilesimleri ve tipta kullanimlari.The antagonist of stimulating amino acids E 4- (4-acetylamino-phenylcarbamoylmethylene) -5,7- dichloro-1,2,3,4-tetrahydro quinoline 2-carboxylic acid (+) enantiomer and salt, processes to prepare them, containing them pharmaceutical compositions and their use in type.

TR1999/02315T 1997-03-26 1998-03-24 Its use as a quinoline-2-carboxylic acid and excitatory amino acid antagonist. TR199902315T2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9706294.7A GB9706294D0 (en) 1997-03-26 1997-03-26 Heterocyclic compound

Publications (1)

Publication Number Publication Date
TR199902315T2 true TR199902315T2 (en) 2000-05-22

Family

ID=10809909

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1999/02315T TR199902315T2 (en) 1997-03-26 1998-03-24 Its use as a quinoline-2-carboxylic acid and excitatory amino acid antagonist.

Country Status (20)

Country Link
EP (1) EP0971896A1 (en)
JP (1) JP2001518901A (en)
KR (1) KR20010005567A (en)
CN (1) CN1257482A (en)
AP (1) AP9901659A0 (en)
AU (1) AU731394B2 (en)
BR (1) BR9808424A (en)
CA (1) CA2284710A1 (en)
EA (1) EA199900755A1 (en)
GB (1) GB9706294D0 (en)
HU (1) HUP0001661A3 (en)
ID (1) ID24306A (en)
IL (1) IL131919A0 (en)
IS (1) IS5186A (en)
NO (1) NO994679L (en)
NZ (1) NZ337793A (en)
PL (1) PL335865A1 (en)
TR (1) TR199902315T2 (en)
WO (1) WO1998042673A1 (en)
YU (1) YU47699A (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9917822D0 (en) * 1999-07-29 1999-09-29 Imperial College Nmda antagonist
DE10132725A1 (en) 2001-07-05 2006-08-03 Grünenthal GmbH Substituted γ-lactone compounds
DE10137487A1 (en) 2001-08-03 2003-03-27 Gruenenthal Gmbh Substituted 5,6,6a, 11b-tetrahydro-7-oxa-6-aza-benzo [c] fluorene-6-carboxylic acid derivatives
DE10306202A1 (en) 2003-02-13 2004-08-26 Grünenthal GmbH 2-(hetero)aryl-2-(N-((hetero)aryl)-amino)-acetic acid derivatives useful e.g. for treating anxiety, inflammation, allergy, depression, diarrhea or especially pain is NMDA antagonist
JP4360891B2 (en) 2003-12-09 2009-11-11 アルパイン株式会社 Electronic device having broadcast receiving function and display method of electronic program guide in the device
RU2451014C2 (en) * 2005-07-22 2012-05-20 Мотида Фармасьютикал Ко., Лтд. Novel heterocyclidene acetamide derivative
PT1908753E (en) * 2005-07-22 2015-02-06 Mochida Pharm Co Ltd Novel heterocyclidene acetamide derivative
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
JP7305560B2 (en) 2017-06-12 2023-07-10 グリテック， エルエルシー Treatment of depression with NMDA antagonists and D2/5HT2A or selective 5HT2A antagonists

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE147732T1 (en) * 1989-03-08 1997-02-15 Merck Sharp & Dohme TETRAHYDROQUINOLINE DERIVATIVES USABLE IN NEURODEGENERATIVE DISEASES
PL186781B1 (en) * 1995-09-29 2004-02-27 Glaxo Wellcome Spa Tetraguinolines as nmda antagonists
GB9617305D0 (en) * 1996-08-17 1996-09-25 Glaxo Wellcome Spa Heterocyclic compounds

Also Published As

Publication number Publication date
WO1998042673A1 (en) 1998-10-01
HUP0001661A3 (en) 2001-12-28
EA199900755A1 (en) 2000-08-28
JP2001518901A (en) 2001-10-16
NO994679L (en) 1999-11-24
CA2284710A1 (en) 1998-10-01
NO994679D0 (en) 1999-09-24
ID24306A (en) 2000-07-13
IS5186A (en) 1999-09-17
NZ337793A (en) 2001-02-23
GB9706294D0 (en) 1997-05-14
BR9808424A (en) 2000-05-23
CN1257482A (en) 2000-06-21
PL335865A1 (en) 2000-05-22
IL131919A0 (en) 2001-03-19
YU47699A (en) 2001-12-26
KR20010005567A (en) 2001-01-15
HUP0001661A2 (en) 2000-09-28
AU7209498A (en) 1998-10-20
AU731394B2 (en) 2001-03-29
AP9901659A0 (en) 1999-09-30
EP0971896A1 (en) 2000-01-19

Similar Documents

Publication Publication Date Title
TR200002015T2 (en) Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors.
CA2473991A1 (en) Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor
TR199900049T2 (en) Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors.
TR199900048T2 (en) Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
BR0308967A (en) Quinoline and isoquinoline derivatives, a process for their preparation and application as inflammation inhibitors
TR199902315T2 (en) Its use as a quinoline-2-carboxylic acid and excitatory amino acid antagonist.
TR199901949T2 (en) From lymphosis to t�m�rler i�in �areler.
TR199800531T1 (en) Tetrahydroquinolines as NMDA antagonists.
TR200002248T2 (en) New dihydroxyhexanoic acid derivatives
DE69614149T2 (en) CHINOLINE DERIVATIVES AS AN ANTIMALARIAN AGENT
TR200103457T2 (en) 4-Phenyl-Pyrimidine Derivatives.
TR200001102T2 (en) Substituted tetrahydropyrimidinene derivatives, their production and uses.
TR200000697T2 (en) Substituted 1,2,3,4,5,6-Hexahydro-2,6-Methano-3-Benzazosin-10-OLs, production methods and their use as pharmaceutical preparations.
DE69922936D1 (en) USE OF INDOL-2,3-DIONE-3-OXIM DERIVATIVES AS AMPA ANTAGONISTS
ATE414100T1 (en) TARGETED LIGAND AGAINST PEYER'S SPOT AND/OR M CELLS
HUP0000882A2 (en) Indole derivatives as nmda (n-methyl-d-aspartate) antagonists and pharmaceutical compositions containing them
TR200000371T2 (en) 3-Substituted 3,4,5,7, - tetrahydro-pyrrolo [3 ', 4': 4,5] thieno [2,3-D] pyrimidine derivatives, their production and use as 5HT-antagonists.
TR199901380A2 (en) Di-ya da triazo-spiro$4.5] dean t�revleri
TR199903159T2 (en) New �-Amino and �-Azido carbonic acid derivatives.
DK1268522T3 (en) LH-RH antagonists as well as their preparation and use thereof as drugs
TR200201503T2 (en) Heterocyclic derivatives.
HUP0002930A2 (en) Method for preparing 3-cyano-2,4-dihalogen-5-fluor-benzoic acid derivatives, intermediates and preparation thereof
BR0113266A (en) Methods for modulating multiple lineage protein kinase and protective compounds that modulate multiple lineage protein kinase
NO20020914D0 (en) Alkoxy-substituted benzimidazole compounds, preparations containing them and their applications
HUP0202895A2 (en) Process to make a sustained release formulation